Clinical Potential of Advanced Glycation End-Product Inhibitors in Diabetes Mellitus

By Menè P.   Festuccia F.   Pugliese F.  

American Journal of Cardiovascular Drugs, Vol. 3, Iss. 5, 2003-01 ,pp. : 315-320

Adis International

Access to resources Recommend Favorite

Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Phase I Study

By Derks Michael   Anzures-Cabrera Judith   Turnbull Lynn   Phelan Mary  

Clinical Drug Investigation, Vol. 31, Iss. 5, 2011-05 ,pp. : 325-335

Adis International

Access to resources Recommend Favorite

A Phase 1 Randomized, Placebo‐Controlled Study Assessing the Pharmacokinetics, Safety, and Tolerability of Retosiban in Healthy, Nonpregnant Japanese Subjects

By  

Clinical Pharmacology In Drug Development, Vol. 7, Iss. 1, 2018-01 ,pp. : 59-66

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Darexaban, an Oral Direct Factor Xa Inhibitor, in Healthy Elderly Japanese Subjects

By  

Clinical Pharmacology In Drug Development, Vol. 2, Iss. 4, 2013-10 ,pp. : 328-335

John Wiley & Sons Inc

Access to resources Recommend Favorite

The effect of paroxetine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects

By Kadokura Takeshi   Adel Martin   Krauwinkel Walter   Takeshige Tetsuo   Nishida Akito  

European Journal of Clinical Pharmacology, Vol. 64, Iss. 6, 2008-06 ,pp. : 605-609

Springer Publishing Company

Access to resources Recommend Favorite